PRINCETON, N.J., March 12 /PRNewswire-FirstCall/ -- Novo Nordisk, a world leader in diabetes care, today announced the appointment of Dr. Alan C. Moses as chief medical officer, North America. In his new role, Dr. Moses, who has been with Novo Nordisk since 2004, will provide strategic input and oversight into the company’s breakthrough diabetes and biopharmaceutical clinical research and medical affairs. In addition, Dr. Moses will work closely with senior colleagues in Denmark on global Novo Nordisk research and development programs in diabetes.
“As the world’s leader in diabetes care, Novo Nordisk is committed to remaining at the forefront of research and development to improve treatments for the patients we serve,” said Dr. Henrik Rasmussen, vice president of clinical development, medical and regulatory affairs, Novo Nordisk. “With his unique clinical expertise, strong relationships in healthcare and leadership abilities, Dr. Moses will have a vital role in working toward Novo Nordisk’s ambition of changing diabetes.”
Dr. Moses was formerly senior vice president and chief medical officer at the Joslin Diabetes Center and joined Novo Nordisk in April of 2004 as associate vice president of medical affairs and since then has also assumed responsibility for clinical research in diabetes.
Prior to joining Novo Nordisk, Dr. Moses spent 23 years at Harvard Medical School affiliated institutions where he rose to the rank of Professor of Medicine. He has written over 100 peer-reviewed articles on the treatment of diabetes and has been recognized both locally and nationally for his research in diabetes and growth factors.
Dr. Moses received a Bachelor of Science from Duke University and a Medical Doctorate from Washington University School of Medicine prior to training at Barnes Hospital in St. Louis, MO, the National Institutes of Health in Bethesda, MD, and Tufts-New England Medical Center in Boston. Dr. Moses is board certified by the American Board of Internal Medicine and has a subspecialty certification in Endocrinology and Metabolism.
Novo Nordisk is a healthcare company with an 80-year history of innovation and achievement in diabetes care. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk’s business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGOPRN Photo Desk, photodesk@prnewswire.comNovo Nordisk
CONTACT: Media - Susan Jackson, +1-609-919-7776; or Investors - ChristianQvist Frandsen, +1-609-919-7937
Web site: http://www.novonordisk-us.com/
